KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Equity Ratio (2023 - 2025)

Biocryst Pharmaceuticals' Equity Ratio history spans 9 years, with the latest figure at 0.23 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 76.12% year-over-year to 0.23; the TTM value through Dec 2025 reached 0.23, up 76.12%, while the annual FY2025 figure was 0.23, 76.12% up from the prior year.
  • Equity Ratio reached 0.23 in Q4 2025 per BCRX's latest filing, up from 0.87 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.23 in Q4 2025 to a low of 1.02 in Q1 2024.
  • Average Equity Ratio over 3 years is 0.83, with a median of 0.9 recorded in 2025.
  • Peak YoY movement for Equity Ratio: plummeted 58.02% in 2024, then skyrocketed 76.12% in 2025.
  • A 3-year view of Equity Ratio shows it stood at 0.88 in 2023, then fell by 10.13% to 0.97 in 2024, then surged by 76.12% to 0.23 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Equity Ratio are 0.23 (Q4 2025), 0.87 (Q3 2025), and 0.92 (Q2 2025).